Business
OncBioMune Submits Phase 2 Protocol to Urology Centers of North Texas
OncBioMune Submits Phase 2 Protocol to Urology Centers of North Texas.
About this update from Theralink Technologies Inc.
[{"type":"text","content":"\n\n BATON ROUGE, La., Feb. 28, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) (\"OncBioMune\" or the \"Company\"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy cancer vaccine technology and targeted cancer therapies, is pleased to inform shareholders that the Company on Tuesday, February 27, 2017 submitted the full protocol for the planned Phase 2 trial of ProscaVax for prostate cancer to Urology Centers of North Texas (UCNT) for review. The submission is subsequent to UCNT recently agreeing to a synopsis of the study as prepared by Dr. Jonathan Head, Chief Executive Officer at OncBioMune.\n Upon review by UCNT, OncBioMune management will make any requisite adjustments and submit the protocol to the U.S. Food and Drug Administration for approval to officially initiate the clinical trial. The trial is designed to build upon a successfully completed Phase 1a trial of ProscaVax in patients with advanced prostate cancer that have failed previous therapy with documented rising prostate specific antigen (PSA). “We are very pleased with the attention that UCNT leadership is dedicating to expeditiously advancing this study,” commented Dr. Head. “Encouraged by successful clinical trials and years of laboratory and additional clinical data, we are optimistic in moving ProscaVax into mid-stage studies and that our novel immunotherapy can provide a meaningful therapeutic response by eliciting an immune response, increasing PSA doubling time and slowing tumor growth where other prostate cancer therapies have failed.” Sign up for OncBioMune email alerts at: http://oncbiomune.com/email-alerts/. About OncBioMune Pharmaceuticals, Inc. OncBioMune Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, based on their proprietary vaccine technology designed to stimulate the immune system to attack tumor cells without damaging healthy tissue. Our lead pipeline product, ProscaVax™, has successfully completed enrollment and vaccination of the prostate cancer patients and is collecting long-term follow-up results for the 1a portion of their Phase 1a/1b clinical trial. Due to the impressive results and proven safety profile of ProscaVax™, OncBioMune is forgoing the 1...